z-logo
open-access-imgOpen Access
The cost‐effectiveness of trastuzumab emtansine (T‐DM1) in HER2‐positive metastatic breast cancer is supported by clinical evidence
Author(s) -
Giuliani Jacopo,
Bonetti Andrea
Publication year - 2021
Publication title -
the breast journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.533
H-Index - 72
eISSN - 1524-4741
pISSN - 1075-122X
DOI - 10.1111/tbj.14024
Subject(s) - medicine , trastuzumab emtansine , trastuzumab , metastatic breast cancer , oncology , breast cancer , cancer

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom